Spain has officially lifted price controls on COVID-19 related products, including face masks and rapid antigen tests, as of March 20, 2026. The move, formalized through Order SND/222/2026 published in the Official State Gazette (BOE), marks the end of exceptional measures implemented in 2020 to ensure public access to essential hygiene and diagnostic tools during the pandemic. This decision reflects a broader shift in public health policy as the acute phase of the COVID-19 crisis subsides and the epidemiological situation stabilizes.
For over six years, the Spanish government intervened in the market to regulate the prices of key items like surgical masks, hygienic masks, hand sanitizers and self-diagnostic tests. These measures were initially enacted through Order SND/354/2020, aiming to prevent price gouging and ensure affordability during a period of high demand and supply chain disruptions. The recent order effectively repeals this earlier legislation, allowing market forces to determine pricing once again.
The Regulatory Shift and Legal Basis
The decision to lift price controls is rooted in the evolving legal framework surrounding public health emergencies. Order SND/222/2026 explicitly revokes the provisions of Order SND/354/2020, which stipulated that the price controls would remain in effect “until determined otherwise by order of the Minister of Health.” This authority was initially granted under Article 94.3 of the consolidated text of the Law on Guarantees and Rational Apply of Medicines and Health Products, which was amended specifically in response to the COVID-19 pandemic. The legal justification for the intervention rested on the state’s power to regulate pharmaceuticals and health products, as outlined in Article 94.3 of the aforementioned law.
The Ministry of Health justified the change by citing principles of necessity, effectiveness, and proportionality, as mandated by Law 39/2015. According to the order, maintaining price controls after the declared end of the health crisis was no longer deemed necessary and would impose unnecessary administrative burdens on the sector. This move aligns with a broader trend towards normalizing healthcare regulations as the immediate threat of the pandemic diminishes. The process of enacting this change involved consultation with affected sectors and autonomous communities, including the cities of Ceuta and Melilla, as well as the Permanent Commission of Pharmacy of the Interterritorial Council of the National Health System.
Products Affected by the Deregulation
The deregulation impacts a range of products previously subject to price controls. These include disposable surgical masks, hygienic masks, and self-diagnostic rapid antigen tests for SARS-CoV-2. The price liberalization extends to skin antiseptics and hydroalcoholic gels and solutions, which were temporarily regulated due to their increased demand during the pandemic. The order effectively nullifies various resolutions issued by the General Directorate for Common Portfolio of Services of the National Health System and Pharmacy that previously dictated maximum retail prices for these items.
This change signifies a return to the general free pricing regime for these products, allowing manufacturers and retailers to set prices based on market conditions. While this may lead to increased price competition, it also raises concerns about potential affordability for vulnerable populations. The Spanish government has not yet announced any compensatory measures to address potential price increases, leaving it to individual consumers and healthcare providers to navigate the fresh market landscape.
Implications for Public Health and Consumer Access
The lifting of price controls on essential COVID-19 prevention and diagnostic tools raises important questions about public health preparedness and equitable access. While the immediate crisis has subsided, the potential for future outbreaks or the emergence of new variants remains a concern. The availability of affordable masks and tests is crucial for early detection and containment of infectious diseases. The removal of price controls could disproportionately affect low-income individuals and families, potentially hindering their ability to protect themselves, and others.
Experts suggest that the long-term impact of this deregulation will depend on several factors, including market competition, production costs, and consumer demand. Increased competition among manufacturers and retailers could lead to lower prices, but this is not guaranteed. Fluctuations in raw material costs and supply chain disruptions could also influence pricing. Monitoring the market closely and implementing appropriate safeguards will be essential to ensure that essential health products remain accessible to all segments of the population. The Spanish Ministry of Health has not indicated whether it will actively monitor prices or intervene if significant price increases are observed.
The decision to end price controls on these products represents a significant step towards normalizing the healthcare landscape in Spain. However, it also underscores the need for ongoing vigilance and proactive measures to protect public health and ensure equitable access to essential medical supplies. The full effect of this deregulation will turn into clearer in the coming months as market forces play out and consumer behavior adapts to the new environment.
The official effectiveness of this liberalization began on March 20, 2026, the day following its official publication. With this step, the Spanish pharmaceutical and health product market closes one of the last regulatory chapters stemming from the 2020 emergency.
Looking ahead, the Ministry of Health will likely focus on strengthening broader public health infrastructure and preparedness for future health crises. Further updates on national health policies and regulations can be found on the Ministry’s official website: http://www.mscbs.gob.es/organizacion/consejoInterterri/home.htm. The next key date to watch is the scheduled review of the National Health System’s pandemic preparedness plan, expected in the fourth quarter of 2026.
What are your thoughts on the lifting of price controls? Share your comments below, and please share this article with your network.